Loading...
•
Dec 31, 2025
Vaxcyte Q4 2025 Earnings Report
Vaxcyte reported its fourth quarter and full year 2025 financial results, highlighting the initiation of the VAX-31 Phase 3 adult clinical program and a strong cash position.
Key Takeaways
Vaxcyte ended 2025 with a robust cash balance of $2.4 billion, further bolstered by a $632.5 million equity offering in early 2026. The company is aggressively advancing its pneumococcal conjugate vaccine (PCV) franchise, specifically VAX-31, into Phase 3 trials for adults and Phase 2 for infants, while scaling up manufacturing capabilities with Lonza.
Initiated the comprehensive VAX-31 adult Phase 3 clinical program (OPUS-1, OPUS-2, and OPUS-3) with topline data expected starting in Q4 2026.
Completed enrollment in the VAX-31 infant Phase 2 dose-finding study with 900 healthy infants dosed.
Maintained a strong balance sheet with $2.44 billion in cash and investments as of year-end 2025, excluding $600.2 million in net proceeds from a February 2026 offering.
Completed construction of a dedicated large-scale manufacturing facility with Lonza to support future commercialization.
Forward Guidance
Vaxcyte is focused on achieving several clinical milestones through 2026 and 2027, supported by its recent capital raise and manufacturing readiness.
Positive Outlook
- OPUS-1 Phase 3 topline data expected in the fourth quarter of 2026.
- OPUS-2 and OPUS-3 Phase 3 data expected in the first half of 2027.
- VAX-31 infant Phase 2 topline data expected by the end of the first half of 2027.
- Expects to initiate Phase 1 adult clinical study for VAX-A1 (Group A Strep) in 2026.
- Manufacturing facility buildout completed within the $350 million budget.
Challenges Ahead
- Net loss increased significantly year-over-year due to higher R&D and personnel costs.
- Operating expenses are expected to remain high as Phase 3 trials progress.
- The company remains clinical-stage with no current product revenue.
- Future commercial success depends on regulatory approvals and BLA submissions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...